. 2018 Aug 29;1(1):9–17. doi: 10.31547/bct-2018-001

Table 2.

Reported outcomes for SAA patients who received URD-SCT

Study	Study design	N	Age, median (range), yr	Conditioning regimen	Graft failure^＊, %	Acute GVHD^†, %	Chronic GVHD, %	OS, %
Kojima et al. (2002)⁶⁷	Registry-based	154	17 (1-46)	TBI+Cy±ATG LFI+Cy±ATG	11	29	30	56 at 5 yr
Bacigalupo et al. (2005)²³	Registry-based	38^‡	14 (3-37)	Flu+Cy+ATG	18	11	27	73 at 2 yr
Deeg et al. (2006)²⁰	Prospective	87	19 (1-53)	Cy+TBI±ATG (TBI; dose de-escalation)	5	NA	43	55 at 7 yr
Bacigalupo et al. (2010)¹⁹	Registry-based	52	13 (3-51)	Flu+Cy+ATG	17	17	23	73 at 5 yr
Bacigalupo et al. (2010)¹⁹	Registry-based	48	27 (7-53)	Flu+Cy+ATG+TBI	17	19	38	79 at 5 yr
Lee et al. (2011)²⁷	Retrospective	50	28 (15-53)	Cy+TBI	2	46	50 at 5 yr	88 at 5 yr
Anderlini et al. (2015)²⁴	Prospective	38	24.5 (0.5-65.9)	Flu+Cy (50 mg/kg) +ATG+TBI	8	24	23 at 1 yr	97 at 1 yr
Anderlini et al. (2015)²⁴	Prospective	41	17.6 (1.9-63.3)	Flu+Cy (100 mg/kg) +ATG+TBI	15	27	32 at 1yr	81 at 1 yr
Park et al. (2017)³⁰	Retrospective	83	30 (17-59)	Cy+TBI±ATG
Park et al. (2017)³⁰	Retrospective	83	30 (17-59)	Group 1^§ Group 2A^§ Group 2B^§	0 1 0	44 62 31	44 at 3 yr 65 at 3 yr 22 at 3 yr	84 at 5 yr 92 at 5 yr 88 at 5 yr

GVHD, acute graft-versus-host disease; OS, overall survival; EBMT, European Group for Blood and Marrow Transplantation; Flu, fludarabine; Cy, cyclophosphamide; ATG, anti-thymocyte globulin; TBI, total body irradiation; LFI, limited field irradiation.

^＊Primary and secondary graft failure

^†Acute GVHD≥grade 2

^‡38 SAA patients who underwent SCT from unrelated (n = 33) or family mismatched (n = 5) donors were enrolled.

^§The patients were divided into two groups: group 1 (n = 25) received HLA-matched (8/8) bone marrow (BM) without ATG; group 2 (n = 58) received SCT from either an HLA-mismatched donor or peripheral blood (PB). Thereafter, group 2 was subdivided according to ATG use into group 2A (without ATG, n = 26), which served as a historical cohort, and group 2B (with ATG, n = 32).